Home › Multiple Sclerosis › NCT05982925
Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders
Longitudinal Investigation of Cortical Demyelination and Meningeal Inflammation in Multiple Sclerosis and Related Disorders
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * 18 years old * able to provide consent in English * able to undergo MRI Exclusion Criteria: * contraindication to MRI * pregnancy
About the study
In this protocol, a combination of MRI, blood, and cerebrospinal fluid (CSF) analysis will be used to understand the natural history, underlying immunologic mechanisms, and clinical implications of central nervous system (CNS) lesions, in particular lesions in the cerebral cortex, in multiple sclerosis (MS) and other inflammatory and autoimmune disorders affecting the CNS. Patients with these disorders, as well as healthy controls, will undergo baseline clinical evaluation and testing, bloodwork, and MRI, with follow up clinical evaluation, bloodwork, and MRI at years 1, 3, and 6. Additional MRIs may be performed in patients with possible new lesion formation or to compare MRI techniques. Lumbar puncture will be performed on participants who are not currently being treated with disease modifying therapies and who are willing to undergo the procedure.
Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 170 · Started: May 6, 2022
Contact the study team
- Erin S Beck, MD, PhD · Phone: 212-241-2474
Official record on ClinicalTrials.gov — NCT05982925
Locations in the U.S.
| New York | Mount Sinai Hospital, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.